Trastuzumab emtansine shows PFS benefit

Sunday 3 June 2012

Roche said that its antibody-drug conjugate, trastuzumab emtansine (T-DM1), has met its co-primary endpoint of a significant improvement in progression-free survival in a Phase 3 study of patients with HER2-positive metastatic breast cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States